Skip to Content

ConjuChem Biotechnologies Inc CCHXF

Rating as of

Morningstar’s Analysis

Valuation
Currency in
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

ConjuChem Biotechnologies Inc is a Canada based biotechnology company. It is primarily engaged in the business of creating novel, next-generation medicines using long-acting therapeutic peptides. The company's compounds are bio-conjugation platforms called Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC). When applied to a given peptide, DAC and PC- DAC can create new drugs with similar therapeutic activities but with longer duration of activity and improved safety profiles. The group's pipeline includes CJC-1134-PC for the treatment of diabetes, PC-DAC Insulin for the treatment of diabetes and DAC HIV for treating HIV.

Contact
225 President-Kennedy Avenue, Suite 3950
Montreal, QC, H2X 3Y8, Canada
T +1 514 844-5558
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Apr 30, 2010
Fiscal Year End Oct 31, 2012
Stock Type
Employees 44